Each December more than 20,000 researchers and clinicians from around the world gather at the annual meeting of American Society of Hematology (ASH) to discuss their most critical findings in the study of new and improved therapies for blood cancer patients.
In conjunction with this year’s conference in Atlanta, GA., The Leukemia & Lymphoma Society (LLS) will host a free education symposium on December 7, entitled “Cellular Metabolism in Hematologic Malignancies: From Evolving Science to Therapeutic Potential.” The program is designed to help hematologists, oncologists and other healthcare professionals enhance their understanding of cellular metabolism and its implications in treating blood cancer patients.
For more than 80 years researchers have recognized that cancer cells exhibit higher than normal glycolysis – converting glucose to lactic acid – but it has only been in the past decade that the reprogramming of cellular metabolism has regained attention for its role in cancer. The symposium presenters will discuss how this metabolic reprogramming contributes to tumor transformation and sustains progression in blood cancer cells, and how these metabolic changes and the genes that control cell metabolism may be potential targets for therapy. After an introduction by Richard C. Winneker, Ph.D, LLS senior vice president of research, the following researchers will discuss their work in this area:
Chi V. Dang, M.D., Ph.D, University of Pennsylvania, “Introduction and Overview: Metabolic Targets in Leukemia & Lymphoma”
Jeffrey C. Rathmell, Ph.D., Duke University, “Metabolism and Apoptotic Pathways in Leukemia”
Mariusz A. Wasik, M.D., University of Pennsylvania, “mTOR Links Cell Signaling and Metabolism”
Ayalew Tefferi, M.D., Mayo Clinic, “Genetic and Metabolic Alterations in Myeloproliferative Neoplasms and AML”
John L. Cleveland, Ph.D., Scripps Research Institute, “Targeting Autophagy in Hematologic Malignancies”
To learn more about this program or to register please visit here.